High-throughput screening to identify inhibitors of breast-to-brain metastasis

高通量筛选以确定乳腺至脑转移的抑制剂

• 批准号: 10688955
• 负责人: Mark Henderson
• 金额: $ 25.96万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688955
• 关键词: Biological Assay; Biology; Brain; Breast; Cells; Collaborations; Disease; Extramural Activities; Goals; Informatics; Life Expectancy; Metastatic malignant neoplasm to brain; Modeling; Pharmaceutical Chemistry; Phenotype; Process; Quality of life; Research; Research Personnel; Synthesis Chemistry; Translations; United States National Institutes of Health; Validation; Woman; Work; assay development; base; brain cell; design; drug development; drug discovery; high throughput screening; in vitro Model; inhibitor; interest; lead optimization; malignant breast neoplasm; new technology; novel; screening; small molecule; small molecule therapeutics; therapeutic candidate; therapeutic development; tool

This project seeks to identify and develop small molecules that target breast-to-brain metastasis. 15-30% of women with stage IV breast cancer develop brain metastases, which negatively impacts life expectancy and quality of life. Small molecule chemotherapeutics that target these metastatic cells are of interest, however, there are a limited number of in vitro models available to identify and develop such therapeutic candidates. During this period, the team focused on design, optimization, and implementation of a high-throughput screening amenable assay using breast-to-brain metastatic cells. Additionally, the team developed a maxtrix assay to identify small molecule combinations that would synergistically kill the brain-metastatic cells.

该项目旨在识别和开发针对乳腺到脑转移的小分子。15-30%的IV期乳腺癌女性发生脑转移，对预期寿命和生活质量产生负面影响。靶向这些转移性细胞的小分子化学治疗剂是令人感兴趣的，然而，存在有限数量的可用于鉴定和开发此类治疗候选物的体外模型。 在此期间，该团队专注于设计，优化和实施使用乳腺至脑转移细胞的高通量筛选检测。 此外，该团队开发了一种最大化试验，以鉴定能够协同杀死脑转移细胞的小分子组合。